FDA Approves Date Rape Drug in Treating Sleep Disorder
The Food and Drug Association (FDA) recently approved the dangerous date rape drug GHB for its first legal use as a medical product in treating a complication of narcolepsy, according to the Associated Press. Despite repeated warnings issued by the FDA and others about the use of GHB in date rape, Xyrem, GHB’s brand name, will now be sold under restricted conditions.
The drug first became notorious as a date rape drug in the 1990s – it became popular for its colorless, odorless quality and ability to knock people out. Reports of GHB being slipped into a woman’s drink to render her immobile or unconscious have since multiplied on college campuses across the country. In the March-April 2000 edition of the FDA’s consumer magazine, a 2000 Glamour magazine survey was cited in which 19 percent of female college students said they knew someone who was the victim of the date-rape drug GHB. “The survey helps to confirm GHB's unfortunate standing as a common date-rape drug along with the infamous Rohypnol and others,” the article reads. In addition, the US Drug Enforcement Agency has cited GHB in at least 58 deaths and 5,700 overdoses since 1990.
GHB was originally developed as a surgical anesthetic, but was quickly pulled off the market because of serious side effects such as depressed breathing, coma, and death. In the 1990s, GHB became known as a relatively inexpensive party drug, a performance enhancer for athletes and bodybuilders, and a sex enhancer. GHB is also known as liquid ecstasy, cherry meth, Easy Lay and Georgia homeboy.
Xyrem, distributed by Orphan Medical Inc., will be used to treat cataplexy, a complication of narcolepsy that is characterized by muscle weakness that can, in its most severe forms, cause victims to collapse during waking hours, according to the Associated Press.
Media Resources: Associated Press, 7/18/02; FDA Consumer Magazine March/April 2000
11/20/2014 Federal Appeals Court Rejects Priests for Life Challenge to Birth Control Coverage Rule - In a victory for women's health, a unanimous panel of the US Court of Appeals for the DC Circuit on Friday rejected a challenge to the Affordable Care Act (ACA) contraceptive coverage benefit brought by Priests for Life, the Roman Catholic Archbishop of Washington and other religiously affiliated non-profit organizations.
Judge Nina Pillard, a former law professor who was nominated to the DC Circuit by President Obama and confirmed by the Senate in December, wrote the opinion for the Court, which found that the ACA birth control benefit did not substantially burden or violate non-profits' religious freedom.
Under the Affordable Care Act, health insurance companies must cover the full cost of all FDA-approved contraceptives - including the pill, IUDs, and emergency contraception - without requiring co-pays or cost-sharing. . . .